Bing He Xu

Summary

Country: China

Publications

  1. pmc Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer
    Xue lian Chen
    Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuan, Chaoyang District, Beijing, 100021, P R China
    Chin J Cancer 35:39. 2016
  2. pmc 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells
    Ruoxi Hong
    Department of Medical Oncology, Cancer Institute and Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
    BMC Cancer 16:725. 2016
  3. ncbi request reprint Effect of hormone therapy on long-term outcomes of patients with human epidermal growth factor receptor 2- and hormone receptor-positive metastatic breast cancer: real world experience in China
    Feng Du
    Department of Medical Oncology, Cancer Institute and Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China E mail
    Asian Pac J Cancer Prev 16:903-7. 2015
  4. pmc There is no association between microRNA gene polymorphisms and risk of triple negative breast cancer in a Chinese Han population
    Fei Ma
    Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
    PLoS ONE 8:e60195. 2013
  5. pmc Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors
    Binghe Xu
    Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
    J Hematol Oncol 4:3. 2011
  6. ncbi request reprint [Docetaxel combined with cisplatin in the treatment of anthracycline-resistant advanced breast cancer]
    Bing He Xu
    Department of Medical Oncology, Cancer Hospital Institute, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China
    Zhonghua Zhong Liu Za Zhi 28:471-3. 2006
  7. ncbi request reprint [Correlation of genetic polymorphisms in nucleotide excision repair system to sensitivity of advanced non-small cell lung cancer patients to platinum-based chemotherapy]
    Peng Yuan
    Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P R China
    Ai Zheng 24:1510-3. 2005
  8. ncbi request reprint [Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial]
    Peng Yuan
    Department of Medical Oncology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
    Zhonghua Zhong Liu Za Zhi 34:465-8. 2012
  9. ncbi request reprint [Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms]
    Peng Yuan
    Department of Medical Oncology, Cancer Institute, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China
    Zhonghua Zhong Liu Za Zhi 28:107-10. 2006
  10. ncbi request reprint [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer]
    Peng Yuan
    Department of Medical Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China
    Zhonghua Yi Xue Za Zhi 85:972-5. 2005

Collaborators

Detail Information

Publications46

  1. pmc Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer
    Xue lian Chen
    Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuan, Chaoyang District, Beijing, 100021, P R China
    Chin J Cancer 35:39. 2016
    ....
  2. pmc 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells
    Ruoxi Hong
    Department of Medical Oncology, Cancer Institute and Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
    BMC Cancer 16:725. 2016
    ....
  3. ncbi request reprint Effect of hormone therapy on long-term outcomes of patients with human epidermal growth factor receptor 2- and hormone receptor-positive metastatic breast cancer: real world experience in China
    Feng Du
    Department of Medical Oncology, Cancer Institute and Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China E mail
    Asian Pac J Cancer Prev 16:903-7. 2015
    ..There are no clinical trials directly comparing the efficacy of hormonal therapy with chemotherapy...
  4. pmc There is no association between microRNA gene polymorphisms and risk of triple negative breast cancer in a Chinese Han population
    Fei Ma
    Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
    PLoS ONE 8:e60195. 2013
    ..No significant association was found between TNBC risk and the SNPs in the miRNA genes in the Chinese Han people (P>0.05), but this warrants further studies...
  5. pmc Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors
    Binghe Xu
    Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
    J Hematol Oncol 4:3. 2011
    ..This phase I, randomized, multicenter, open-label study investigated the pharmacokinetics, safety, and efficacy of the oral mammalian target of rapamycin inhibitor everolimus in Chinese patients with advanced solid tumors...
  6. ncbi request reprint [Docetaxel combined with cisplatin in the treatment of anthracycline-resistant advanced breast cancer]
    Bing He Xu
    Department of Medical Oncology, Cancer Hospital Institute, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China
    Zhonghua Zhong Liu Za Zhi 28:471-3. 2006
    ..To evaluate the efficacy and safety of combination chemotherapy of Docetaxel (Taxotere, TXT) combined with cisplatin (DDP) for anthracycline (ANT)-resistant advanced breast cancer (ABC)...
  7. ncbi request reprint [Correlation of genetic polymorphisms in nucleotide excision repair system to sensitivity of advanced non-small cell lung cancer patients to platinum-based chemotherapy]
    Peng Yuan
    Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P R China
    Ai Zheng 24:1510-3. 2005
    ..This study was to examine the correlations of polymorphisms in nucleotide excision repair system to sensitivity of advanced non-small cell lung cancer (NSCLC) to platinum-based chemotherapy...
  8. ncbi request reprint [Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial]
    Peng Yuan
    Department of Medical Oncology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
    Zhonghua Zhong Liu Za Zhi 34:465-8. 2012
    ....
  9. ncbi request reprint [Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms]
    Peng Yuan
    Department of Medical Oncology, Cancer Institute, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China
    Zhonghua Zhong Liu Za Zhi 28:107-10. 2006
    ..This study examined the relationship between p53 and p73 genetic polymorphisms and the response to platinum-based chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)...
  10. ncbi request reprint [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer]
    Peng Yuan
    Department of Medical Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China
    Zhonghua Yi Xue Za Zhi 85:972-5. 2005
    ....
  11. ncbi request reprint [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients]
    Ping Zhang
    Department of Medical Oncology, Chinese Academy of Medical Sciences, Beijing 100021, China
    Zhonghua Zhong Liu Za Zhi 33:381-4. 2011
    ..To characterize the sites of distant recurrence and clinical outcomes in a cohort of Chinese patients with metastatic triple-negative breast cancer (TNBC)...
  12. ncbi request reprint [Safety of adjuvant dose-dense chemotherapy with paclitaxel and epirubicin for high-risk breast cancer]
    Wei Hua Wu
    Department of Medical Oncology, Cancer Hospital Institute, Chinese Academy of Medical Sciences, Beijing 100021, China
    Zhonghua Zhong Liu Za Zhi 30:548-51. 2008
    ..To investigate the safety and tolerance of adjuvant dose-dense chemotherapy with paclitaxel and epirubicin for high-risk breast cancer...
  13. ncbi request reprint [Single nucleotide polymorphisms in XRCC1 and clinical response to platin-based chemotherapy in advanced non-small cell lung cancer]
    Zhong hua Wang
    Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China
    Ai Zheng 23:865-8. 2004
    ..This study examined the association between genetic polymorphisms of DNA repair gene XRCC1 and response to cisplatin- or carboplatin-based chemotherapy of advanced non-small cell lung cancer (NSCLC)...
  14. doi request reprint [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer]
    Wen Yue Ma
    Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
    Zhonghua Zhong Liu Za Zhi 34:770-4. 2012
    ..To evaluate the efficacy, safety and survival of combination of carboplatin plus paclitaxel as neoadjuvant chemotherapy (NACT) for patients with locally advanced triple-negative breast cancer (TNBC), and explore an optimal regimen for TNBC...
  15. doi request reprint [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases]
    Qian Li
    Department of Medical Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
    Zhonghua Zhong Liu Za Zhi 35:207-11. 2013
    ..To analyze the clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases...
  16. ncbi request reprint [Clinical analysis of 34 patients with adrenal metastasis from breast cancer]
    Qiao Li
    Department of Medical Oncology, Cancer Hospital Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
    Zhonghua Zhong Liu Za Zhi 35:855-7. 2013
    ..To evaluate the clinical characteristics and prognosis of adrenal metastasis from breast cancer, and to explore methods to improve prognosis...
  17. ncbi request reprint [Clinical value of trastuzumab in the treatment of lapatinib-resistant HER2-positive metastatic breast cancer]
    Fei Ma
    Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
    Zhonghua Zhong Liu Za Zhi 35:521-4. 2013
    ..g. lapatinib. The aim of the present study was to evaluate retrospectively the clinical value of trastuzumab in patients with lapatinib-resistant HER2-positive advanced breast cancer treated in our center...
  18. ncbi request reprint [Clinical characteristics and potential prognostic factors of breast cancer patients with liver metastases]
    Jia Yu Wang
    Department of Medical Oncology, Cancer Hospital Institute, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China
    Zhonghua Zhong Liu Za Zhi 28:612-6. 2006
    ..To analyze the clinical characteristics, efficiency of treatment and potential prognostic factors of breast cancer patients with liver metastases (BCLM)...
  19. ncbi request reprint [Clinical characteristics and prognosis of breast cancer patients with vascular invasion]
    Wei Hong Zhao
    Department of Medical Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China
    Zhonghua Zhong Liu Za Zhi 29:137-40. 2007
    ..To analyze the clinicopathological features, parameters of molecular biology, survival rate, and prognostic factors in breast cancer patients with vascular invasion...
  20. ncbi request reprint [Endobronchial metastases from breast cancer: a clinicopathological and survival analysis]
    Jian Li
    Department of Medical Oncology, Chinese Academy of Medical Sciences, Beijing, China
    Zhonghua Zhong Liu Za Zhi 34:394-7. 2012
    ..The most common extrathoracic malignancies associated with EBM are colorectal, renal and breast cancer. This study aimed to evaluate the clinicopathological aspects of EBM from breast cancer and the prognosis of the patients...
  21. ncbi request reprint [Clinical features and prognosis in breast cancer patients over 70 years of age]
    Wei Hong Zhao
    Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China
    Zhonghua Zhong Liu Za Zhi 28:385-8. 2006
    ..To investigate the clinical characteristics and prognostic factors in breast cancer patients over 70 years of age...
  22. ncbi request reprint [Analysis of clinicopathological characteristics and prognosis for triple negative breast cancer: a report of 108 cases]
    Yin Guan
    Department of Medical Oncology, Cancer Hospital Institute, Chinese Academy of Medical Science, Beijing 100021, China
    Zhonghua Zhong Liu Za Zhi 30:196-9. 2008
    ....
  23. ncbi request reprint [Effects of polysomy 17 on HER-2 gene and protein expression and its clinicopathologic significance in breast cancer]
    Jian Li
    Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
    Zhonghua Yi Xue Za Zhi 93:84-8. 2013
    ..To explore the effects of polysomy 17 on human epidermal growth factor receptor-2 (HER-2) testing and study its clinicopathologic significance...
  24. ncbi request reprint [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients]
    Yin Guan
    Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China
    Zhonghua Yi Xue Za Zhi 88:77-81. 2008
    ..To analyze the clinical characteristics, survival, and prognosis of female breast cancer patients with 10 or more positive lymph nodes...
  25. ncbi request reprint Correlation between serum HER-2 oncoprotein and patients with breast cancer
    Peng Yuan
    Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021
    Chin Med Sci J 19:212-5. 2004
    ..To detect serum HER-2 oncoprotein levels in patients with operable and metastatic breast cancers, and to study the correlations between serum HER-2 level and lymph node status as well as other clinical parameters...
  26. ncbi request reprint [Effects of anastrozole on lipid metabolism in Chinese postmenopausal women with breast cancer]
    Han Hong Lu
    Department of Medical Oncology, Chinese Academy of Medical Sciences, Beijing, China
    Zhonghua Zhong Liu Za Zhi 33:520-5. 2011
    ..The aim of this study was to evaluate the effect of anastrozole, a new generation aromatase inhibitor, on the lipid metabolism in postmenopausal Chinese women with early breast cancer, and observe the adverse reactions as well...
  27. ncbi request reprint [Clinicopathological characteristics and prognostic significance of young patients with triple-negative breast cancer]
    Ping Zhang
    Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
    Zhonghua Zhong Liu Za Zhi 32:128-31. 2010
    ..To investigate the clinicopathological characteristics and prognosis in young patients with estrogen receptor (ER)-negative, progesterone receptor(PR)-negative, and Her-2-negative (triple-negative) breast cancer (TNBC)...
  28. ncbi request reprint [Prognostic factors and analyses of different therapeutic strategies in HR+ breast cancer patients with bone-only metastases]
    Xiao Yan Ding
    Cancer Hospital and Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
    Zhonghua Yi Xue Za Zhi 92:3279-82. 2012
    ..To explore the therapeutic outcomes of various first-line regimens and prognostic factors for hormone receptor positive (HR+) breast cancer (BrCa) patients with bone-only metastases...
  29. ncbi request reprint [Characteristics and prognostic factors of postoperative chemotherapy for female breast cancer patients under 30 years of age: a report of 129 patients]
    Zhong hua Wang
    Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China
    Zhonghua Zhong Liu Za Zhi 27:111-3. 2005
    ..To analyze the clinical characteristics, survival and prognosis of breast cancer patients under 30 years of age...
  30. ncbi request reprint [Goserelin plus anastrozole in the treatment of premenopausal patients with metastatic breast cancer]
    Shu Yang Yao
    Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China
    Zhonghua Yi Xue Za Zhi 90:526-8. 2010
    ..To investigate the efficacy and safety of goserelin plus anastrozole in advanced premenopausal breast cancer patients...
  31. ncbi request reprint [Clinical features and prognostic factors of small breast cancer with multiple axillary lymph node metastasis]
    Yu qian Liao
    Department of Medical Oncology, Cancer Hospital Institute, Chinese Acadamy of Medical Sciences, Peking Union Medical College, Beijing 100021, China
    Zhonghua Zhong Liu Za Zhi 29:615-8. 2007
    ..To analyse the clinical features and prognostic factors of small breast cancer patient (T < or =2 cm) with multiple axillary lymph node metastasis (N > or =4)...
  32. ncbi request reprint [XRCC1 and XPD genetic polymorphisms predict clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer]
    Peng Yuan
    Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
    Zhonghua Zhong Liu Za Zhi 28:196-9. 2006
    ..The purpose of this study was to examine the association between polymorphisms in XRCC1 and XPD, which are involved in DNA repair, and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC)...
  33. doi request reprint [Association of genetic variantions of circadian clock genes and risk of breast cancer]
    Wen Miao Wang
    Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
    Zhonghua Zhong Liu Za Zhi 35:236-9. 2013
    ..To investigate the relationship between genetic variantions of circadian clock genes and risk of breast cancer...
  34. doi request reprint Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer
    Yi Yin
    Department of Medical Oncology, Chinese Academy of Medical Sciences, Beijing, 100021, China
    J Huazhong Univ Sci Technolog Med Sci 33:262-5. 2013
    ..Further study is needed to validate these results...
  35. ncbi request reprint Oral etoposide monotherapy is effective for metastatic breast cancer with heavy prior therapy
    Peng Yuan
    Department of Medical Oncology, Cancer Hospital, Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
    Chin Med J (Engl) 125:775-9. 2012
    ..This study is a single-arm clinical trial that evaluates the efficacy and safety of short-term oral etoposide in Chinese patients with MBC who had received heavy prior therapy...
  36. ncbi request reprint Paclitaxel plus carboplatin for women with advanced breast cancer
    Ju Liu
    Department of Medical Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021
    Chin Med Sci J 22:93-7. 2007
    ..To evaluate the efficacy and safety of combination chemotherapy with paclitaxel and carboplatin for advanced breast cancer (ABC)...
  37. ncbi request reprint [Relationship between P-glycoprotein function in peripheral blood cells and multidrug resistance in breast carcinoma]
    Fei Ma
    Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
    Zhonghua Zhong Liu Za Zhi 32:529-32. 2010
    ..To analyze the relationship between P-glycoprotein function in peripheral blood cells and primary multidrug resistance in breast carcinoma...
  38. ncbi request reprint [Inflammatory breast cancer: 38 cases clinical report]
    Jing Huang
    Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, P R China
    Ai Zheng 21:888-91. 2002
    ..Inflammatory breast cancer (IBC) is a special form of rapidly progressive breast cancer with poor prognosis. The purpose of this study was to investigate the clinical characters, treatment, and prognosis of inflammatory breast cancer...
  39. ncbi request reprint [Comparison of fluorescence in situ hybridization and immunohistochemistry assessment for Her-2 status in breast cancer and its relationship to clinicopathological characteristics]
    Hui Hui Li
    Department of Medical Oncology, Cancer Hospital Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
    Zhonghua Yi Xue Za Zhi 91:76-80. 2011
    ....
  40. ncbi request reprint Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer
    Bai lin Zhang
    Center of Breast Diseases and Department of Abdominal Surgery, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
    Chin Med J (Engl) 124:199-204. 2011
    ..The aim of this research was to examine the effects of genetic polymorphisms in CYP3A, GSTP1 and MDR1 genes on treatment response and side-effects of breast cancer patients receiving EPI/CTX chemotherapy...
  41. ncbi request reprint [Serum her-2/neu level and related factors in patients with breast cancer]
    Peng Yuan
    Department of Medical Oncology, Cancer Institute Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China
    Zhonghua Zhong Liu Za Zhi 25:573-4. 2003
    ..To detect serum her-2/neu level in patients with breast cancer of different stages and its relationship with tissue her-2/neu overexpression as well as other factors...
  42. ncbi request reprint Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer: findings from the ATHENA study
    Bing He Xu
    Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing 100021, China
    Chin Med J (Engl) 125:764-9. 2012
    ....
  43. pmc Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients
    Bing He Xu
    Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing 100021, P R China
    Chin J Cancer 30:327-35. 2011
    ..639) or PFS (P = 0.989). These data confirm that the lapatinib plus capecitabine combination is an effective and well-tolerated treatment option for Chinese women with heavily pretreated MBC, irrespective of PIK3CA status...
  44. ncbi request reprint [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression]
    Ying Fan
    Department of Medical Oncology, Cancer Hospital Institute, Chinese Acadamy of Medical Sciences, Beijing 100021, China
    Zhonghua Zhong Liu Za Zhi 30:917-20. 2008
    ..To evaluate the clinicopathological characteristics and prognosis of breast cancer with estrogen- and progesterone-receptor negative (ER-/PR-) and HER-2 overexpression (HER+++) in a Chinese population...
  45. ncbi request reprint [Strategy in the treatment of anthracycline-resistant breast cancer]
    Bing He Xu
    Zhonghua Zhong Liu Za Zhi 29:241-4. 2007
  46. ncbi request reprint [Basic Consensus on endocrinotherapy for breast cancer]
    Ze Fei Jiang
    Zhonghua Zhong Liu Za Zhi 28:238-9. 2006